Floatz logo

Liraglutide

Metastatic

Seoul Hospitalprotein_peptidePhase 1Active
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Metastatic cohort.

Asset / SponsorPhaseRating
azd6244
AstraZeneca
Phase 3BB
Zactima
Sanofi
Phase 2B
DACARBAZINE
AstraZeneca
Phase 3B
Vcn-01
Theriva Biologics SL
Phase 2B
Docetaxel
Sanofi
Phase 2B

View all 29 →

Same molecule, other indications

Liraglutide is also rated in:

metabolic diseaseDormant
A
Indicative ·
84 / 100
View asset →
polycystic ovary syndromeDormant
BBB
Indicative ·
79 / 100
View asset →
type 2 diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →